Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents

Clinical and Experimental Immunology

Volumn 177, Issue 3, 2014, Pages 630-640

  Picchianti Diamanti, A ^a   Rosado, M M ^b   Scarsella, M ^b   Germano, V ^a   Giorda, E ^b   Cascioli, S ^b   Lagana B ^a   D'Amelio, R ^a   Carsetti, R ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Abatacept; B cell subsets; CTLA 4 Ig; Regulatory T cells; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MIDDLE AGED; PLASMA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ABATACEPT; B CELL SUBSETS; CTLA-4-IG; REGULATORY T CELLS; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; HUMANS; IMMUNOCONJUGATES; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904748906     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12367     Document Type: Article

References (50)

1. Genovese MC, Bathon JM, Martin RW etal. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46:1443-1450.
2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903-911.
3. Pieper J, Johansson S, Snir O etal. Peripheral and site-specific CD4(+) CD28(null) T cells from rheumatoid arthritis patients show distinct characteristics. Scand J Immunol 2014; 79:149-155.
4. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233-258.
5. Caux C, Vanbervliet B, Massacrier C etal. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994; 180:1841-1847.
6. Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray G, Nadler LM. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci USA 1993; 90:11059-11063.
7. Jeannin P, Delneste Y, Lecoanet-Henchoz S, Gauchat JF, Ellis J, Bonnefoy JY. CD86 (B7-2) on human B cells. A functional role in proliferation and selective differentiation into IgE- and IgG4-producing cells. J Biol Chem 1997; 272:15613-15619.
8. Walunas TL, Lenschow DJ, Bakker CY etal. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-413.
9. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11:852-863.
10. Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov 2006; 5:185-186.
11. Bonelli M, Ferner E, Goschl L etal. Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum 2013; 65:599-607.
12. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13:227-242.
13. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995. J Immunol 2011; 186:3808-3821.
14. Lee JH, Wang LC, Lin YT, Yang YH, Lin DT, Chiang BL. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 2006; 117:280-286.
15. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199:971-979.
16. Gavin MA, Rasmussen JP, Fontenot JD etal. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007; 445:771-775.
17. Yamaguchi T, Kishi A, Osaki M etal. Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression. Proc Natl Acad Sci USA 2013; 110:E2116-2125.
18. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev 2004; 197:179-191.
19. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 2002; 359:540-541.
20. Arnett FC, Edworthy SM, Bloch DA etal. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-324.
21. Kruetzmann S, Rosado MM, Weber H etal. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003; 197:939-945.
22. Capolunghi F, Cascioli S, Giorda E etal. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol 2008; 180:800-808.
23. Avery DT, Kalled SL, Ellyard JI etal. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112:286-297.
24. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44:1313-1319.
25. Pers JO, Daridon C, Devauchelle V etal. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 2005; 1050:34-39.
26. Genovese MC, Schiff M, Luggen M etal. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 2012; 39:1546-1554.
27. Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25 (5 Suppl. 46):S46-56.
28. Buch MH, Boyle DL, Rosengren S etal. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009; 68:1220-1227.
29. Pieper J, Herrath J, Raghavan S, Muhammad K, Vollenhoven R, Malmstrom V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol 2013; 14:34.
30. Scarsi M, Zanotti C, Chiarini M etal. Reduction of peripheral blood T cells producing IFN-gamma and IL-17 after therapy with abatacept for rheumatoid arthritis. Clin Exp Rheumatol 2014; 32:204-210.
31. Scarsi M, Ziglioli T, Airo P. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol 2011; 38:2105-2111.
32. Blache C, Lequerre T, Roucheux A etal. Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept. Rheumatology (Oxf) 2011; 50:1814-1822.
33. reg imbalance in patients with rheumatoid arthritis. J Clin Immunol 2011; 31:596-605.
34. Huang Z, Yang B, Shi Y etal. Anti-TNF-alpha therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis. Cell Immunol 2012; 279:25-29.
35. Ehrenstein MR, Evans JG, Singh A etal. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277-285.
36. Moreland LW, Baumgartner SW, Schiff MH etal. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141-147.
37. Weinblatt ME, Kremer JM, Bankhurst AD etal. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-259.
38. Maini RN, Breedveld FC, Kalden JR etal. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552-1563.
39. de la Torre I, Leandro MJ, Edwards JC, Cambridge G. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab. Clin Exp Rheumatol 2012; 30:554-560.
40. Nishimoto N, Hashimoto J, Miyasaka N etal. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66:1162-1167.
41. Bristol-Myers Squibb Company. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125118s0138lbl.pdf (accessed December 2011).
42. Smolen JS, Landewe R, Breedveld FC etal. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964-975.
43. Mellor AL, Chandler P, Baban B etal. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2, 3 dioxygenase. Int Immunol 2004; 16:1391-1401.
44. Grohmann U, Orabona C, Fallarino F etal. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3:1097-1101.
45. Boussiotis VA, Nadler LM, Strominger JL, Goldfeld AE. Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci USA 1994; 91:7007-7011.
46. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004; 172:3422-3427.
47. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184:1397-1411.
48. Anolik JH, Ravikumar R, Barnard J etal. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008; 180:688-692.
49. Singh JA, Wells GA, Christensen R etal. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; (2):CD008794.
50. Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L etal. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 2011; 31:588-595.